Vincerx Pharma Statistics
Total Valuation
Vincerx Pharma has a market cap or net worth of $1.70 million. The enterprise value is -$6.01 million.
Important Dates
The next estimated earnings date is Friday, March 28, 2025.
Earnings Date | Mar 28, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Vincerx Pharma has 2.24 million shares outstanding. The number of shares has increased by 47.84% in one year.
Current Share Class | 2.24M |
Shares Outstanding | 2.24M |
Shares Change (YoY) | +47.84% |
Shares Change (QoQ) | +5.11% |
Owned by Insiders (%) | 8.49% |
Owned by Institutions (%) | 10.71% |
Float | 2.05M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.19 |
P/TBV Ratio | 0.27 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.17, with a Debt / Equity ratio of 0.18.
Current Ratio | 2.17 |
Quick Ratio | 2.06 |
Debt / Equity | 0.18 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -217.55% and return on invested capital (ROIC) is -120.37%.
Return on Equity (ROE) | -217.55% |
Return on Assets (ROA) | -85.42% |
Return on Invested Capital (ROIC) | -120.37% |
Return on Capital Employed (ROCE) | -295.81% |
Revenue Per Employee | n/a |
Profits Per Employee | -$643,571 |
Employee Count | 42 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.12% in the last 52 weeks. The beta is 1.17, so Vincerx Pharma's price volatility has been higher than the market average.
Beta (5Y) | 1.17 |
52-Week Price Change | -99.12% |
50-Day Moving Average | 2.56 |
200-Day Moving Average | 9.09 |
Relative Strength Index (RSI) | 25.36 |
Average Volume (20 Days) | 430,750 |
Short Selling Information
The latest short interest is 108,516, so 4.85% of the outstanding shares have been sold short.
Short Interest | 108,516 |
Short Previous Month | 269,217 |
Short % of Shares Out | 4.85% |
Short % of Float | 5.30% |
Short Ratio (days to cover) | 0.80 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -28.17M |
Pretax Income | -28.90M |
Net Income | -27.03M |
EBITDA | -28.12M |
EBIT | -28.17M |
Earnings Per Share (EPS) | -$17.22 |
Full Income Statement Balance Sheet
The company has $10.09 million in cash and $1.64 million in debt, giving a net cash position of $8.45 million or $3.77 per share.
Cash & Cash Equivalents | 10.09M |
Total Debt | 1.64M |
Net Cash | 8.45M |
Net Cash Per Share | $3.77 |
Equity (Book Value) | 9.11M |
Book Value Per Share | 5.80 |
Working Capital | 6.32M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -27.97M |
Capital Expenditures | n/a |
Free Cash Flow | -27.97M |
FCF Per Share | -$12.49 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Vincerx Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -47.84% |
Shareholder Yield | -47.84% |
Earnings Yield | -1,107.27% |
FCF Yield | -1,145.57% |
Analyst Forecast
The average price target for Vincerx Pharma is $40.00, which is 5,162.47% higher than the current price. The consensus rating is "Buy".
Price Target | $40.00 |
Price Target Difference | 5,162.47% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on January 28, 2025. It was a reverse split with a ratio of 0.05:1.
Last Split Date | Jan 28, 2025 |
Split Type | Reverse |
Split Ratio | 0.05:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |